Contact
searchSearch
HMP Global

News

News
131I-LNTH-1095 Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
04/10/2026
Stephanie Holland
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW...
04/10/2026
Radiopharmaceutical Education Institute
News
131I-LNTH-1095 Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
04/10/2026
Stephanie Holland
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW...
04/10/2026
Radiopharmaceutical Education Institute
Press Release
HMP Global’s Radiopharmaceutical Education Institute (RPEI) Aims to Advance Oncology Innovation
03/12/2026
HMP Global today announced the launch of the Radiopharmaceutical Education Institute (RPEI), a new clinician-focused educational platform from Oncology Learning Network (OLN), dedicated to advancing the science and clinical integration of...
HMP Global today announced the launch of the Radiopharmaceutical Education Institute (RPEI), a new clinician-focused educational platform from Oncology Learning Network (OLN), dedicated to advancing the science and clinical integration of...
HMP Global today announced the...
03/12/2026
Radiopharmaceutical Education Institute
FDA Approval
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
News
Iopofosine I 131 Shows Durable Responses in Heavily Pretreated Waldenström Macroglobulinemia
02/12/2026
Emily Estrada
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug...
02/12/2026
Radiopharmaceutical Education Institute
News
¹⁸F-DOPA-PET Detects Early Treatment Response in IDH-Mutant Glioma
02/06/2026
Stephanie Holland
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world...
02/06/2026
Radiopharmaceutical Education Institute
News
¹⁸F-DOPA-PET Detects Early Treatment Response in IDH-Mutant Glioma
02/06/2026
Stephanie Holland
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world...
02/06/2026
Radiopharmaceutical Education Institute
News
177Lu-Edotreotide Extends Progression-Free Survival vs Everolimus in GEP-NETs
10/28/2025
Janelle Bradley
¹⁷⁷Lu-edotreotide significantly improved progression-free survival and objective response rates compared to everolimus in patients with advanced GEP-NETs, with consistent benefits across tumor grades, sites, and prior treatment settings,...
¹⁷⁷Lu-edotreotide significantly improved progression-free survival and objective response rates compared to everolimus in patients with advanced GEP-NETs, with consistent benefits across tumor grades, sites, and prior treatment settings,...
¹⁷⁷Lu-edotreotide significantly...
10/28/2025
Radiopharmaceutical Education Institute
News
212Pb-DOTAMTATE Demonstrates Promising Activity After Prior PRRT in Advanced GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE achieved a 30.8% objective response rate and a 96% disease control rate with a manageable safety profile in patients with advanced SSTR-positive GEP-NETs who had progressed following prior...
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE achieved a 30.8% objective response rate and a 96% disease control rate with a manageable safety profile in patients with advanced SSTR-positive GEP-NETs who had progressed following prior...
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute
News
212Pb-DOTAMTATE Yields Durable and Deep Responses in PRRT-Naïve GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute

Advancing Oncology Through Radiopharmaceutical Innovation

The Radiopharmaceutical Education Institute (RPEI) is dedicated to advancing the science and clinical integration of radiopharmaceutical therapies in oncology. Through accessible, expert-driven education and multidisciplinary dialogue, we aim to equip clinicians with the insight and evidence needed to inform treatment decisions and shape the future of radiopharmaceutical innovation in cancer care.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use